Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. - Wikidata - awgldk - TriplyDB

Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains.

Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains.

http://www.wikidata.org/entity/Q39782948

about

Parkinson's disease: gene therapies Parkinson's disease gene therapy: success by design meets failure by efficacy Gene-based therapy of Parkinson's Disease: Translation from animal model to human clinical trial employing convection enhanced delivery Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue?Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease Enhanced delivery and bioactivity of the neurturin neurotrophic factor through focused ultrasound-mediated blood--brain barrier opening in vivo.Of monkeys and men: analysis of the phase 2 double-blind, sham-surgery controlled, randomized trial of AAV2-neurturin gene therapy for Parkinson's disease.Fiber-modified adenovirus for central nervous system Parkinson's disease gene therapy.α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons.Chronic levodopa administration followed by a washout period increased number and induced phenotypic changes in striatal dopaminergic cells in MPTP-monkeys Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain.NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.Recombinant adenoassociated virus 2/5-mediated gene transfer is reduced in the aged rat midbrain.Differential effects of two MRI contrast agents on the integrity and distribution of rAAV2 and rAAV5 in the rat striatum.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum.Activin A Inhibits MPTP and LPS-Induced Increases in Inflammatory Cell Populations and Loss of Dopamine Neurons in the Mouse Midbrain In Vivo.Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease A regulatable AAV vector mediating GDNF biological effects at clinically-approved sub-antimicrobial doxycycline doses.TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson's disease via CNTF.Direct and retrograde transduction of nigral neurons with AAV6, 8, and 9 and intraneuronal persistence of viral particles The pharmacology of regenerative medicine Gene therapy for misfolding protein diseases of the central nervous system.Pathways of infusate loss during convection-enhanced delivery into the putamen nucleus Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients.Disease duration and the integrity of the nigrostriatal system in Parkinson's disease Adeno-associated Virus-mediated, Mifepristone-regulated Transgene Expression in the Brain.Implementing neuronal plasticity in NeuroAIDS: the experience of brain-derived neurotrophic factor and other neurotrophic factors.Impact of age and vector construct on striatal and nigral transgene expression.Antioxidant gene therapy against neuronal cell death.Glial Cell Line-Derived Neurotrophic Factor Gene Delivery in Parkinson's Disease: A Delicate Balance between Neuroprotection, Trophic Effects, and Unwanted Compensatory Mechanisms.Future treatments for Parkinson's disease: surfing the PD pipeline.Axonal degeneration as a therapeutic target in the CNS.Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?AAV2-neurturin (CERE-120) for Parkinson's disease.A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.Obstacles to the development of a neuroprotective therapy for Parkinson's disease.Gene therapy for Parkinson's disease: state-of-the-art treatments for neurodegenerative disease.Therapeutic prospects for Parkinson disease.

P2860

Q26824184-7AC727D8-22EA-4D99-9928-13C96DC12A88 Q26851325-A0BB2B14-82ED-4148-9148-01CE5D49AA59 Q26851517-CA1DBCC1-EDF2-4D32-92F2-8487D006D4F8 Q27002651-E254D44D-D2F1-45E2-8F52-1892D7FB42EE Q27023715-641EEEC9-4CDB-4991-88DB-53551E9C4EA8 Q27309140-DB66EEE2-017D-4978-AF77-81D092FE4B05 Q30387126-1FEFDD00-B53C-4CF9-A66D-D7A5D14BFFBE Q33877296-05F3FACE-AB78-4428-A950-96430AD4ACCD Q34102305-0ADA6DB0-05C8-42A6-81B8-11B2BA1B17AA Q34503671-0F74108C-E3E6-4D0A-A3AA-66E33166805D Q34506001-75B0DFAC-E617-44F8-8E53-886D08860D44 Q34892014-409D1347-9298-4AF9-B697-E6979ADF77E0 Q35017493-D37FA3FE-C911-47BE-BB26-FC7258B26EEA Q35044451-D093413A-AC94-401A-AB6D-A010A5C2E647 Q35194954-4D79252E-252A-4E1B-BFD2-068BCAB2C609 Q35614156-856EC7BA-33AD-48F2-BC8C-58B972D35D67 Q35751582-4A64D36B-FBFD-4518-894D-A52933BF8ED0 Q36259630-E5A75D6C-33ED-4A27-AEF0-492BCCF64F4F Q36713101-8392A4F1-6E27-42BF-B550-4AC601078F9F Q36744851-A26F808A-864F-46DA-A409-A3AA61C0F73C Q36824652-BB630B42-E246-4E6B-9BAB-B347A38CF7B8 Q36945745-892E3D49-C474-41BB-B81A-B5F6969D4D92 Q36974665-32ED87E7-5F4A-4AD6-9853-E900C6D73D4C Q36983203-903F08B2-EC68-4D70-A15A-AE1ECFFCAF07 Q37026271-F9146745-1870-4926-977A-8BE498FA4679 Q37027502-FF8CFB4E-4162-4C4F-8E1C-45A1A760334D Q37043102-A390C1C8-8712-4891-A7F5-C52908C4D86E Q37065552-5CAA1DCE-2BF8-4A7D-8CFB-1ADBF1251DE9 Q37351271-FE1B7E87-0A88-461B-B2A3-10DB1629214E Q37481547-D4E38AA3-1A98-4A1A-9063-10B2702E2CA9 Q37647941-08719965-F2BB-4E54-9327-4ABBBF94246E Q37742852-43A76E07-0AAB-42B8-817E-EFD8E4322F2D Q37950428-C5C416B8-498C-498A-8C23-E29781CC2723 Q37990880-39A92FB6-564F-44F2-88C0-A4B40D823BC9 Q38021661-73B0FF2C-7037-4EF5-A3C9-8ED36BD3BB75 Q38066256-51CA8B03-B72C-4B65-A7BD-E53FC6E2F876 Q38075068-DDF03CA5-BB12-4154-AA6F-54A3D156C6A7 Q38079790-22DA7BD8-98B4-4CD3-9212-8989FCD585F8 Q38112216-98F840D9-10C7-45B8-90DD-185C135AACFB Q38137889-797F3326-3114-45EC-9228-06F0145D2A43

P2860

Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains.

http://www.wikidata.org/entity/Q39782948

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Bioactivity of AAV2-neurturin ...... e and nonhuman primate brains.

@en

Bioactivity of AAV2-neurturin gene therapy

@nl

type

label

Bioactivity of AAV2-neurturin ...... e and nonhuman primate brains.

@en

Bioactivity of AAV2-neurturin gene therapy

@nl

prefLabel

Bioactivity of AAV2-neurturin ...... e and nonhuman primate brains.

@en

Bioactivity of AAV2-neurturin gene therapy

@nl

P1433

Q39782948-C1D44F44-909E-4E1F-846B-F503DA416DA7

P1476

Q39782948-7F4DD751-AD97-4EFA-9A94-548E98C241BE

P2093

Q39782948-0DB3DE03-0C27-4489-80EA-69565B88F806

Q39782948-129FFD9E-3E33-4B0D-A8E3-3F6B7E003A6E

Q39782948-1C0154AF-691F-4048-A38F-2F3A1262E2F7

Q39782948-9294949C-111D-4296-91F4-1A4CF012520B

Q39782948-940441B4-D3D8-4081-8B28-1549FBEA39A0

Q39782948-B6FE83C6-3C85-4ED0-8A81-6BDF14D588B4

Q39782948-BA44A765-B430-4633-AB62-8674432FA25D

Q39782948-BE788661-1FD6-4010-A8E2-7010467537E9

Q39782948-CBB83934-D65D-478C-B479-8AD874471EF6

Q39782948-D792B850-86B1-42DA-A87E-56D49633E35D

P2860

Q39782948-027DEEE2-0AA7-470C-A33A-027620B31BF6

Q39782948-03AD6662-C73D-4A5B-9574-11A5437FD763

Q39782948-0DE1018F-2C90-4B00-9D55-BC6E9AB97104

Q39782948-21AEC243-EC9B-4DD8-BC15-21E521C19B93

Q39782948-2A9B0CBF-E0CC-4B7E-B90E-2C6ECB9DCA7D

Q39782948-454BFD48-8839-47AA-86AA-89893E092EAE

Q39782948-4704EDF4-B38F-434B-866D-F571877592C7

Q39782948-4C0D183E-0813-4E66-961C-1EB24156C521

Q39782948-53BFC597-3E37-4FB5-86CA-2E85F621B6BE

Q39782948-59124CEE-E3B7-49B8-824F-BC6B6E45DF19

P304

Q39782948-50D820A9-CA45-4087-AE6B-24BD09F2988A

P31

Q39782948-D1ADAD01-4188-460B-9244-776D7E74DC7B

P356

Q39782948-62EDA9D2-96F6-48C6-AF37-53EEE516F7CF

P407

Q39782948-75E31098-33F3-47D7-AF43-C33091208940

P433

Q39782948-86621575-912B-4D54-BB1B-1AF595B528A2

P478

Q39782948-B6501C1A-8A4B-4ACC-B67F-C58DE04293B1

P50

Q39782948-10B92663-E865-4CD3-9242-86DA428EF0BA

Q39782948-3F867D4D-61FE-47F0-B4BA-29381EA66302

P577

Q39782948-3679EB68-D3CB-451F-AE8D-FB055898C18A

P5875

Q39782948-BC4ADD50-15BE-42B8-87B9-4FC0CDC31828

P698

Q39782948-CA531E13-1538-4898-9E95-CCB872105790

P921

Q39782948-617FD9C9-11E0-45D8-BE51-0DB4FB65CE79

Q39782948-8D4EC2E1-3FA5-4009-915A-9E85F1B41D29

P932

Q39782948-42BC7C85-A59C-4E63-8F32-956ED129C30D

P356

P1433

Movement Disorders

P1476

Bioactivity of AAV2-neurturin ...... se and nonhuman primate brains

@en

P2093

Alistair Wilson

http://www.w3.org/2001/XMLSchema#string

C Warren Olanow

http://www.w3.org/2001/XMLSchema#string

Christopher D Herzog

http://www.w3.org/2001/XMLSchema#string

Elliott J Mufson

http://www.w3.org/2001/XMLSchema#string

Eugene M Johnson

http://www.w3.org/2001/XMLSchema#string

Jeffrey H Kordower

http://www.w3.org/2001/XMLSchema#string

Joao Siffert

http://www.w3.org/2001/XMLSchema#string

Lamar Brown

http://www.w3.org/2001/XMLSchema#string

Raymond T Bartus

http://www.w3.org/2001/XMLSchema#string

Yaping Chu

http://www.w3.org/2001/XMLSchema#string

P2860

Functional recovery in parkinsonian monkeys treated with GDNF

Role of axonal transport in neurodegenerative diseases

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

Crossroads in GDNF therapy for Parkinson's disease

Axonal transport defects: a common theme in neurodegenerative diseases

AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease

Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo

Localized striatal delivery of GDNF as a treatment for Parkinson disease.

On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis.

Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases.

P304

27-36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.23442

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

C Warren Olanow

Jeffrey H Kordower

P577

2010-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49836932

http://www.w3.org/2001/XMLSchema#string

P698

21322017

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

6333467

http://www.w3.org/2001/XMLSchema#string